Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer

Johnson & Johnson announced Phase 1b/2 OrigAMI-4 study results showing subcutaneous amivantamab combined with pembrolizumab and carboplatin achieved a 77% overall response rate in first-line treatment of advanced recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) other than HPV-associated oropharyngeal cancer. Complete responses were observed in 14% of patients, with 65% of responses remaining ongoing at median follow-up of 10.6 months. These findings support continued evaluation in the ongoing Phase 3 OrigAMI-5 study.